Milatuzumab: A promising new agent for the treatment of lymphoid malignancies

Expert Opinion on Investigational Drugs

Volumn 18, Issue 1, 2009, Pages 99-104

  Mark, Tomer ^a   Martin, Peter ^a   Leonard, John P ^a   Niesvizky, Ruben ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CD74; HLL1; Lymphoma; Milatuzumab; Monoclonal antibody; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MILATUZUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MEDLINE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHARMACODYNAMICS; REVIEW; UNSPECIFIED SIDE EFFECT; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; LYMPHOMA;

EID: 67649386125     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780802636162     Document Type: Review

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006 (Pubitemid 23095683)
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242 • This is a landmark study that demonstrated the potential for rituxumab to enhance the efficacy of chemotherapy in non-Hodgkin's lymphoma. (Pubitemid 34438862)
4. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391
5. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127 (Pubitemid 46638950)
6. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545
7. Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997;8:675-680 (Pubitemid 27372166)
8. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-3785
9. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) signifi cantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732 (Pubitemid 41742196)
10. Munshi N, Tricot G, Barlogie B. Plasma cell neoplasms. In: DeVita JVT, Hellman S, Rosenberg SA, ediors, Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkons; 2001; p. 2465-2499
11. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873
12. Zojer N, Kirchbacher K, Vesely M, et al. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006;47:1103-1109 (Pubitemid 44102973)
13. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25:72-81 (Pubitemid 34052837)
14. Moreau P, Voillat L, Benboukher L, et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2007;21:835-836 (Pubitemid 46444580)
15. Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clin Cancer Res 2007;13:s5636-42 • Review of current therapeutic modalities for non-Hodgkin's lymphomas, including chemotherapeutics and immune-based treatment combinations. (Pubitemid 47515265)
16. Morshhauser F, Leonard JP, Coiffier B, et al. Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. J Clin Oncol 2006;24:S429-S429
17. Hagenbeek A, Plesner T, Johnson P, et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a Phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma. Blood 2005;106:B270-B270
18. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-5051 (Pubitemid 46224011)
19. Hussein MA, Berenson JR, Niesvizkyl R, et al. Results of a Phase I trial of SGN-40 (anti-huCD40 mAb) in patients with relapsed multiple myeloma. Blood 2006;108:A1021-A1021
20. Friedberg JW, Leonard JP, Younes A, et al. Updated results from a Phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory, follicular NHL. Blood 2005;106:A685-A685
21. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259-293 •• Essential description of the MHCII molecule and transport system. (Pubitemid 24140416)
22. Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300 (Pubitemid 126733578)
23. Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 1999;98:296-302 (Pubitemid 29487653)
24. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-1476 (Pubitemid 36686708)
25. Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program. J Biol Chem 2001;276:27203-27206 (Pubitemid 37410631)
26. Ishigami S, Natsugoe S, Tokuda K, et al. Invariant chain expression in gastric cancer. Cancer Lett 2001;168:87-91 (Pubitemid 32463917)
27. Young AN, Amin MB, Moreno CS, et al. Expression profi ling of renal epithelial neoplasms: a method for tumor classifi cation and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-1651 (Pubitemid 32422929)
28. Ioachim HL, Pambuccian SE, Hekimgil M, et al. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol 1996;20:64-71 (Pubitemid 26007711)
29. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:s5556-63 • A review of the prior scientific and preclinical literature for the use of milatuzumab. (Pubitemid 47510387)
30. Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10:6606-6611 (Pubitemid 39346557)
31. Leung SO, Goldenberg DM, Dion AS, et al. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol 1995;32:1413-1427 (Pubitemid 26064907)
32. Losman MJ, Hansen HJ, Dworak H, et al. Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer 1997;80:2660-2666 (Pubitemid 28009524)
33. Roche PA, Teletski CL, Stang E, et al. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA 1993;90:8581-8585 (Pubitemid 23277713)
34. Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104:3705-3711 •• This article outlines experiments demonstrating both the in vitro and the in vivo activity of milatuzumab in cell lines and mouse models of NHL and MM. (Pubitemid 39564448)
35. Stein R, Goldenberg DM. Improved therapy of multiple myeloma by combining milatuzumab (Anti-CD74 humanized mAb) and bortezomib: In vitro and in vivo results. Blood 2007;110:A356-7
36. Chang CH, Sapra P, Vanama SS, et al. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106:4308-4314 (Pubitemid 41775941)
37. Griffiths GL, Mattes MJ, Stein R, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9:6567-6571 (Pubitemid 38031846)
38. Sapra P, Stein R, Pickett J, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11:5257-5264 (Pubitemid 41003714)
39. Lundberg BB, Griffi ths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release 2004;94:155-161 (Pubitemid 37542385)
40. Govindan SV, Goldenberg DM, Elsamra SE, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. J Nucl Med 2000;41:2089-2097 (Pubitemid 32038701)
41. Sapra P, Chang CH, Vanama S, et al. Preclinical Safety and Efficacy of Two Novel Immunotoxins Consisting of Ranpirnase (Rap) Fused to an Internalizing Anti-CD74 Humanized IgG4 Antibody in Human Non-Hodgkin's Lymphoma Xenografts. ASH Annual Meeting Abstracts. 2005;106:346